Literature DB >> 25787032

Goserelin loaded nanoparticles inhibit growth and induce apoptosis in human prostate cancer cell lines.

Priti Tomar1, Neeti Jain, G S Agarwal, V K Dixit.   

Abstract

Goserelin acetate (Gos) is a synthetic analogue of luteinizing hormone-releasing hormone (LHRH) used in treatment of prostate cancer. The objective of this study is to investigate the in vitro cytotoxic effect of Goserelin loaded nanoparticles on both androgen dependent and androgen independent cell lines. Goserelin causes cell death of prostate cancer cell lines by inducing apoptosis. Treatment of Goserelin loaded nanoparticles inhibited the proliferation of LNCaP and DU145 in the dose-dependent manner, however did not affect the cell proliferation in PC-3 cell lines. Blank nanoparticles exhibited negligible cytotoxicity on cell lines. In addition, immunocytochemical studies indicated that Gos induced apoptosis in prostate cancer cells. The presence and characteristics of LHRH receptors and their messenger ribonucleic acid (mRNA) expression in human prostate cancer cell line LNCaP were investigated by polymerase chain reaction. Changes in nuclear morphology and DNA fragmentation associated with Gos induced apoptosis were clearly seen in both LNCaP and DU145 cell lines by DNA studies. The PCR product of the expected size of 319 bp for human LHRH receptors was obtained in cell line sample. Goserelin loaded nanoparticles are the potential tool for site specific delivery for prostate cancer treatment.

Entities:  

Year:  2012        PMID: 25787032     DOI: 10.1007/s13346-012-0082-2

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  23 in total

1.  Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth.

Authors:  Daniel Peternac; Irena Klima; Marco G Cecchini; Urs E Studer; George N Thalmann
Journal:  J Urol       Date:  2006-07       Impact factor: 7.450

2.  Detection of mRNA expression of gonadotropin-releasing hormone and its receptor in normal and neoplastic rat prostates.

Authors:  H L Lau; X M Zhu; P C Leung; L W Chan; G F Chen; P S Chan; K L Yu; F L Chan
Journal:  Int J Oncol       Date:  2001-12       Impact factor: 5.650

3.  Effects of triptorelin, a gonadotropin-releasing hormone agonist, on the human prostatic cell lines PC3 and LNCaP.

Authors:  L Ravenna; L Salvatori; S Morrone; C Lubrano; M R Cardillo; F Sciarra; L Frati; F Di Silverio; E Petrangeli
Journal:  J Androl       Date:  2000 Jul-Aug

4.  LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.

Authors:  G N Thalmann; R A Sikes; T T Wu; A Degeorges; S M Chang; M Ozen; S Pathak; L W Chung
Journal:  Prostate       Date:  2000-07-01       Impact factor: 4.104

5.  Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells.

Authors:  Evangelos C Gryparis; Maria Hatziapostolou; Evangelia Papadimitriou; Konstantinos Avgoustakis
Journal:  Eur J Pharm Biopharm       Date:  2007-01-12       Impact factor: 5.571

Review 6.  Treatment of metastatic carcinoma of the prostate.

Authors:  H Goethuys; L Baert; H Van Poppel; G Lieskovsky; L W Brady; Z Petrovich
Journal:  Am J Clin Oncol       Date:  1997-02       Impact factor: 2.339

Review 7.  Gonadotropin-releasing hormone and its analogs.

Authors:  P M Conn; W F Crowley
Journal:  Annu Rev Med       Date:  1994       Impact factor: 13.739

8.  Structure-activity study on the LH- and FSH-releasing and anticancer effects of gonadotropin-releasing hormone (GnRH)-III analogs.

Authors:  Magdolna Kovács; Borbála Vincze; Judit E Horváth; János Seprodi
Journal:  Peptides       Date:  2007-01-13       Impact factor: 3.750

Review 9.  Development of prostate cancer treatment: the good news.

Authors:  Samuel R Denmeade; John T Isaacs
Journal:  Prostate       Date:  2004-02-15       Impact factor: 4.104

10.  Preparation and evaluation of PEG-PCL nanoparticles for local tetradrine delivery.

Authors:  Rutian Li; Xiaolin Li; Li Xie; Dan Ding; Yong Hu; Xiaoping Qian; Lixia Yu; Yitao Ding; Xiqun Jiang; Baorui Liu
Journal:  Int J Pharm       Date:  2009-06-12       Impact factor: 5.875

View more
  2 in total

1.  Evaluation of the Biological Properties and the Enzymatic Stability of Glycosylated Luteinizing Hormone-Releasing Hormone Analogs.

Authors:  Shayli Varasteh Moradi; Pegah Varamini; Istvan Toth
Journal:  AAPS J       Date:  2015-05-09       Impact factor: 4.009

Review 2.  Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy.

Authors:  Thy Pham; Martin C Sadowski; Huika Li; Derek J Richard; Michael C d'Emden; Kerry Richard
Journal:  Exp Hematol Oncol       Date:  2016-06-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.